Head-To-Head Review: BioNTech (NASDAQ:BNTX) and Codiak BioSciences (NASDAQ:CDAK)

Codiak BioSciences (NASDAQ:CDAK – Get Rating) and BioNTech (NASDAQ:BNTX – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for Codiak BioSciences and BioNTech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codiak BioSciences	0	1	0	0	2.00
BioNTech	0	7	6	0	2.46

Codiak BioSciences currently has a consensus price target of $4.20, suggesting a potential upside of 38,081.82%. BioNTech has a consensus price target of $172.20, suggesting a potential upside of 63.58%. Given Codiak BioSciences’ higher possible upside, research analysts clearly believe Codiak BioSciences is more favorable than BioNTech.

Earnings & Valuation

This table compares Codiak BioSciences and BioNTech’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codiak BioSciences	$33.57 million	0.01	-$37.16 million	($0.69)	-0.02
BioNTech	$18.24 billion	1.40	$9.94 billion	$26.01	4.05

BioNTech has higher revenue and earnings than Codiak BioSciences. Codiak BioSciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

71.3% of Codiak BioSciences shares are held by institutional investors. Comparatively, 15.3% of BioNTech shares are held by institutional investors. 8.2% of Codiak BioSciences shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Codiak BioSciences and BioNTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Codiak BioSciences	-51.13%	-109.51%	-34.44%
BioNTech	51.03%	32.52%	27.56%

Volatility and Risk

Codiak BioSciences has a beta of 3.71, indicating that its stock price is 271% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.

Summary

BioNTech beats Codiak BioSciences on 11 of the 14 factors compared between the two stocks.

About Codiak BioSciences

(Get Rating)

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About BioNTech

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.